XML 10 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACQUISITION (Details 1) (USD $)
Dec. 29, 2011
Cash and cash equivalents $ 10,386
Other assets 90,770
In-process research and development acquired 5,441,839
Total identifiable assets 5,542,995
Accounts payable and accrued expenses 197,191
Total identifiable liabilities 5,794,509
Net identifiable liabilities (251,514)
Goodwill 629,752
Total 378,238
Icon and Swiss Pharma [Member]
 
Notes payable (ICON and Swiss Pharma) 939,718
Excluding Icon and Swiss Pharma [Member]
 
Notes payable (ICON and Swiss Pharma) $ 4,657,600